Menu
Live
Market Overview
Live indices, gainers & losers
Market Pulse
AI-curated live updates
Market Movers
Top gainers & losers by cap
Market Signals
Value, momentum & analyst signals
Smart Money
Insider & congress trades
Hedge Funds
What 63 elite funds bought & sold
52-Week Highs
Stocks breaking out to new highs
52-Week Lows
Beaten-down stocks near support
High Beta
Stocks that move more than the market
Earnings Calendar
Upcoming earnings dates
Daily
Research
Invest
LIVE
Septerna Inc
SEPN
NASDAQ·Healthcare·Biotechnology·Mkt cap $1.6B
$34.00
▼ -1.76%
View full research view
Our plain-language verdict, the thesis, risk factors, and what is changing about the business.
View research view52-Week Range
$10.62 - $37.99
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 203.6% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary GPCR drug discovery and development platform enabling oral small molecule candidates for traditionally difficult targets
- Experienced management team with deep expertise in GPCR biology and clinical development
- First-mover advantage in oral formulations for specific GPCR indications with limited treatment options
- Diversified pipeline across high-value therapeutic areas with significant market opportunities
Bear Case
2 risks
- High volatility (beta 2.4). Larger-than-normal price swings expected.
- Growth premium of 0.0x vs Biotech & Therapeutics peers. Reasonable for this growth rate.
Growth
Stable outlook
Clinical trial progression of SEP-786, SEP-631, and TSHR programs toward potential regulatory approvals
Value
Growth premium of 0.0x vs Biotech & Therapeutics peers. Reasonable for this growth rate.
Momentum
Hot
+37.5% over 3m
Quality
Excellent
High-growth business (500% revenue growth, 99% gross margin). Pre-profit but investing in growth.
Dividend
None
No dividend
Smart-money signal
Who's buying SEPN right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: May 21, 2026
MAY 12, 2026
Reported EPS of -$0.19 vs -$0.42 consensus (+54.4% surprise). Revenue of $26.5M vs $17.0M expected (+56.3%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Q2 26
+54.4%
Next: May 21, 2026
Revenue trend · last 8Q
—
—
+80%
-31%
-68%
+12113%
+11276%
+12011%
Q2 24
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
$370.0K
$176.0K
$212.0K
$219.0K
$119.0K
$21.5M
$24.1M
$26.5M
Margins · last 8Q
Gross
—
Operating
—
Profit
-32.6%
Wall Street consensus
6 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: Guggenheim · Jul 1, 2026